NanoViricides, Inc. (NYSE American: NNVC) has received regulatory approval from the local agency ACOREP in the Democratic Republic of Congo (DRC) to conduct a Phase II clinical trial of its investigational drug NV-387 Oral Gummies for the treatment of the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The announcement, made via a press release, marks a significant step in the company’s efforts to combat a deadly disease that has already claimed nearly 1,900 lives in the DRC.
The trial will be managed by Om Sai Clinical Research Private Limited, a contract research organization, with initial preparations already underway to accelerate the first patient dosing. NanoViricides has confirmed that sufficient quantities of the oral gummy formulation are already in the DRC, ready for use. This logistical preparedness could be crucial in a region where healthcare infrastructure is often challenged.
The significance of an oral treatment for Ebola cannot be overstated. Current standard treatments for Ebola, such as intravenous monoclonal antibodies, require trained medical personnel, cold chain storage, and sterile conditions—resources that are often scarce in remote outbreak zones. An oral gummy, which can be administered without specialized equipment, could simplify treatment delivery, reduce the burden on healthcare workers, and potentially allow for earlier intervention. This is particularly important in a country like the DRC, where outbreaks often occur in rural areas with limited access to hospitals.
The World Health Organization has reported 4,141 confirmed cases and 1,889 confirmed deaths from the current Bundibugyo ebolavirus outbreak as of Aug. 6, 2026. The high mortality rate underscores the urgent need for effective and accessible treatments. NV-387 is designed to be a broad-spectrum antiviral that mimics host-side features required by viruses for infection, thereby potentially inhibiting a wide range of viral pathogens. The oral formulation could offer a practical advantage in resource-limited settings, as noted by the company.
NanoViricides is a clinical-stage company focused on developing nanomedicines for antiviral therapy. Its technology is based on the TheraCour nanomedicine platform, which it licenses exclusively for multiple viral indications. The company’s lead candidate, NV-387, is also being developed for other viral infections, including respiratory viruses like RSV and influenza, as well as poxviruses and measles. The Ebola trial represents a significant expansion of the drug’s potential applications.
The approval for this trial is a critical milestone for NanoViricides, as it advances the company’s pipeline and validates the potential of its platform. However, as with any drug development, there are inherent risks. The company cautions that successful results in the lab or even in early-stage trials do not guarantee success in later-stage clinical trials or regulatory approval. The path to market for any pharmaceutical product is lengthy and requires substantial capital.
Despite these challenges, the initiation of a Phase II Ebola trial in an active outbreak setting is a notable development. It not only provides a potential new tool to combat a deadly disease but also demonstrates the feasibility of conducting clinical research in challenging environments. If the trial shows promise, it could pave the way for a more accessible treatment option for Ebola, potentially saving countless lives in future outbreaks.
For more information on the press release, visit https://ibn.fm/2Pqu0. For the latest news on NanoViricides, see the company’s newsroom at https://ibn.fm/NNVC.
